Satellos Bioscience Inc.
Satellos Bioscience Inc.
Your view on MSLE
Overview
What the company does, where it operates, and who runs it.
About Satellos Bioscience Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Frank Gleeson
- Headquarters
- Royal Bank Plaza, Toronto, ON, CA
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Frank Gleeson
- Headquarters
- Royal Bank Plaza, Toronto, ON, CA
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo.
It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease.
The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Satellos Bioscience Inc., and the rating behind it. MSLE last traded at $7.63; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Satellos Bioscience Inc.. Starting points for Satellos Bioscience Inc.: EPS -$1.68, beta 1.17 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Satellos Bioscience Inc.. Satellos Bioscience Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Satellos Bioscience Inc.. Trailing twelve-month EPS for Satellos Bioscience Inc. stands at -$1.68. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Satellos Bioscience Inc.. Satellos Bioscience Inc. has reported as a listed company since 2012. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Satellos Bioscience Inc. valued side by side against its closest peers. Satellos Bioscience Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Satellos Bioscience Inc., and how their positions are changing. At a $9.8M market value, institutional positions materially move Satellos Bioscience Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Satellos Bioscience Inc. executives and directors. Shares of Satellos Bioscience Inc. have traded between $4.85 and $13.39 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Satellos Bioscience Inc.. Satellos Bioscience Inc. is a $9.8M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Satellos Bioscience Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Satellos Bioscience Inc.. Coverage tracks Satellos Bioscience Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.